Amplify Weight Loss Drug & Treatment ETF THNR is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 51.9% from its 52-week low price of $18.56/share.
Are more gains in store for this ETF? Let us take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed.
THNR in Focus
The underlying VettaFi Weight Loss Drug & Treatment Index comprises of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. The product charges 59 bps in annual fees.
Why the Move?
Weight-loss drug market has been in a hot pot lately. The ETF has large weights in Novo Nordisk NVO and Eli Lilly LLY. Both stocks have an individual weight of more than 10% of the fund. With each of the stocks gaining more than 2% on May 30, 2025, the fund had every reason to surge.
More Gains Ahead?
The ETF THNR might falter on its strong performance in the near term, with a negative weighted alpha of 12.86.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
